Results 231 to 240 of about 156,514 (326)

Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world edoxaban concentrations in older patients receiving reduced‐dose regimens. Low trough concentrations (< 12 ng/mL) were associated with an increased risk of thromboembolism. Among patients meeting the ELDERCARE‐AF criteria, low drug levels were more frequent with the 15 mg regimen than with the 30 mg regimen.
Sung‐Chun Tang, Shin‐Yi Lin, Chih‐Hao Chen, Yen‐Bin Liu, Li‐Ting Ho, Ching‐Hua Kuo, Yu‐Fong Peng, Chih‐Fen Huang, Jiann‐Shing Jeng   +8 more
wiley   +1 more source

Oral mouthwashes for asymptomatic to mildly symptomatic adults with COVID-19 and salivary viral load: a randomized, placebo-controlled, open-label clinical trial [PDF]

Daisuke Onozuka, Satoko Takatera, Hiroo Matsuo, Hisao Yoshida, Shigeto Hamaguchi, Shungo Yamamoto, Ryuichi Minoda Sada, Koichiro Suzuki, Keiji Konishi, Satoshi Kutsuna   +9 more
openalex   +1 more source

Correction: Placebo Effects of Open-label Verbal Suggestions on Itch.

Acta dermato-venereologica
This corrects the article DOI: 10.2340/00015555-2823.
openaire   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Neural and molecular changes during a mind-body reconceptualization, meditation, and open label placebo healing intervention [PDF]

Alex Jinich‐Diamant, Sierra Simpson, Juan Pablo Zuniga-Hertz, Ramamurthy Chitteti, Jan M. Schilling, Jacqueline A. Bonds, Laura K. Case, Andrei V. Chernov, Joe Dispenza, Jacqueline Maree, Neil Stahl, Michael Licamele, Narin Fazlalipour, Swetha Devulapalli, Leonardo Christov‐Moore, Nicco Reggente, Michelle A. Poirier, Tobias Moeller‐Bertram, Hemal H. Patel   +18 more
openalex   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

Clinical effects of cyclosporine A on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials [PDF]

, 2016

core   +1 more source

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension

Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jeanine Kamphuis, Jan Spijker, Annemarie van der Meij, Antoinette D. I. van Asselt, Marije aan het Rot, Robert A. Schoevers   +7 more
openalex   +2 more sources

Efficacy of a probiotic supplement as an intervention for the symptoms of depression: A double-blind, randomised, placebo-controlled trial, open label extension and 6 month follow-up

, 2015
Amy R. Romijn
openalex   +2 more sources